Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Phase 3positiveretatrutidePositive
AI Analysis
Summary
Eli Lilly's retatrutide demonstrated positive Phase 3 results in two obesity trials (TRIUMPH-2 and TRIUMPH-3), showing significant weight loss and A1C improvements in patients with obesity, type 2 diabetes, and cardiovascular disease.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
TRIUMPH-2: Adults with obesity/overweight and type 2 diabetes lost up to 49.6 lbs (20.8%) at 80 weeks. TRIUMPH-3: Adults with severe obesity and established cardiovascular disease showed significant weight and A1C improvements.
Importance:8/10
Sentiment:
0.85
Phase 3ObesityType 2 DiabetesWeight LossCardiovascular DiseaseGLP-1Triple Agonist
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 23, 2026 10:45 AM